Cardiovascular outcomes trials for weight loss interventions another tool for cardiovascular prevention?

Ian J. Neeland; Darren K. McGuire; Naveed Sattar

doi:10.1161/CIRCULATIONAHA.121.056742

Cardiovascular outcomes trials for weight loss interventions another tool for cardiovascular prevention?

Ian J. Neeland, Darren K. McGuire, Naveed Sattar

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1359-1361
Number of pages	3
Journal	Circulation
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.121.056742
State	Accepted/In press - 2021
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIRCULATIONAHA.121.056742

Cite this

@article{ccc5633176c94ddfb3459818cd350f59,

title = "Cardiovascular outcomes trials for weight loss interventions another tool for cardiovascular prevention?",

author = "Neeland, {Ian J.} and McGuire, {Darren K.} and Naveed Sattar",

note = "Funding Information: Ian J. Neeland reports personal fees from Boehringer Ingelheim/Lilly Alliance, Merck, and Nestle Health Sciences. Darren K. McGuire reports personal fees from Boehringer Ingelheim, Janssen Research and Development LLC, Sanofi US, Merck & Co, Merck Sharp & Dohme Corp, Eli Lilly USA, NovoNordisk, GlaxoSmithKline, AstraZeneca, Lexicon Pharmaceuticals, Eisai, Pfizer, Metavant, Applied Therapeutics, Afimmune, and Esperion. Naveed Sattar reports personal fees from Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and grant funding paid to his university from AstraZeneca, Boehringer Ingelheim, and Roche Diagnostics.",

year = "2021",

doi = "10.1161/CIRCULATIONAHA.121.056742",

language = "English (US)",

pages = "1359--1361",

journal = "Circulation",